Core Viewpoint - Reviva Pharmaceuticals Holdings, Inc. has announced a public offering of 27 million shares of common stock and associated warrants, aiming to raise approximately $9 million to fund research and development and for general corporate purposes [1][3]. Group 1: Offering Details - The public offering includes 27,000,000 shares of common stock and Series E and Series F warrants, priced at $0.335 per share, with total gross proceeds expected to be around $9 million before expenses [1][3]. - The Series E Warrants and Series F Warrants will have an exercise price of $0.335 per share, with Series E Warrants expiring in five years and Series F Warrants expiring in 12 months [2]. Group 2: Use of Proceeds - The net proceeds from the offering are intended to support research and development activities, working capital, and other general corporate purposes [3]. Group 3: Company Overview - Reviva is a late-stage biopharmaceutical company focused on developing therapies for unmet medical needs in CNS, inflammatory, and cardiometabolic diseases, with a pipeline that includes two drug candidates, brilaroxazine (RP5063) and RP1208 [6].

Core Viewpoint - Rithm Capital Corp. has initiated an opportunistic underwritten public offering of Series E Fixed-Rate Cumulative Redeemable Preferred Stock, contingent on market conditions [1] Group 1: Offering Details - The terms of the Preferred Stock will be determined through negotiations between the Company and the underwriters [1] - The Company plans to apply for listing the Preferred Stock on the New York Stock Exchange under the symbol "RI" [1]

Core Viewpoint - Red Cat Holdings, Inc. has announced a public offering of 15,625,000 shares at a price of $9.60 per share, aiming to raise approximately $150 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The offering is expected to close on or about September 19, 2025, subject to customary closing conditions [1]. - Underwriters have a 30-day option to purchase up to 2,343,750 additional shares at the public offering price [1]. - Northland Capital Markets is the sole bookrunner, with Ladenburg Thalmann & Co. Inc. acting as co-manager for the transaction [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for general corporate and working capital purposes, including operating expenditures related to the new unmanned surface vessel division [2]. Group 3: Company Overview - Red Cat Holdings, Inc. is a U.S.-based provider of advanced drone and robotic solutions for defense and national security [5]. - The company develops American-made hardware and software through its subsidiaries, Teal Drones and FlightWave Aerospace, supporting military, government, and public safety operations [5]. - Red Cat is expanding into the maritime domain with its Blue Ops, Inc., focusing on uncrewed surface vessels (USVs) to enhance safety and mission effectiveness [5].

Core Viewpoint - AIRO Group Holdings, Inc. has successfully closed an upsized underwritten public offering of 4,830,000 shares of its common stock, indicating strong investor interest and confidence in the company's aerospace and defense technologies [1] Summary by Relevant Sections - **Offering Details** - The offering included the full exercise of the underwriters' option to purchase an additional 630,000 shares, demonstrating robust demand [1] - The gross proceeds from the offering, before deducting underwriting discounts and other expenses, highlight the financial strength of the company [1] - **Company Profile** - AIRO Group Holdings, Inc. specializes in advanced aerospace and defense technologies, positioning itself in a critical and growing industry [1]

Group 1 - Nebius Group N.V. announced the pricing of its underwritten public offering of $1 billion of Class A ordinary shares at a price of $92.50 per share [1] - The company has granted underwriters a 30-day option to purchase an additional $150 million of Class A ordinary shares [1]

Core Viewpoint - AIRO Group Holdings, Inc. has announced the pricing of its upsized underwritten public offering of 4,200,000 shares at a price of $18.50 per share, indicating strong market interest and potential for capital raising [1] Company Summary - AIRO Group specializes in advanced aerospace and defense technologies, positioning itself in a growing sector with increasing demand for innovative solutions [1] - The gross proceeds from the offering are expected to be significant, although the exact amount after deducting underwriting discounts and commissions has not been specified [1]

Group 1 - Veritone, Inc. has announced the pricing of an underwritten public offering of 9,505,705 shares of its common stock at a price of $2.63 per share [1] - The aggregate gross proceeds from this offering are expected to be approximately $25 million before deducting underwriting discounts and commissions [1]

Core Viewpoint - Mineralys Therapeutics, Inc. has successfully closed a public offering of 11,274,509 shares of common stock, raising approximately $287.5 million before expenses, to fund the development of its product candidate lorundrostat and for general corporate purposes [1][2]. Group 1: Offering Details - The public offering price was set at $25.50 per share, which included the full exercise of the underwriters' option to purchase an additional 1,470,588 shares [1]. - The offering was managed by BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel, and Wells Fargo Securities, with LifeSci Capital as the lead manager [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for clinical development of lorundrostat, including research, development, manufacturing, and pre-commercialization activities, as well as for working capital and general corporate purposes [2]. Group 3: Company Overview - Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for hypertension and related comorbidities, including chronic kidney disease and obstructive sleep apnea, driven by dysregulated aldosterone [5]. - The company's initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor [5].

Core Viewpoint - Nova LifeStyle, Inc. has successfully closed a public offering of 9,836,054 shares of common stock and 19,672,108 warrants, raising approximately $9.0 million in gross proceeds, which will be utilized for working capital, marketing, debt repayment, and capital expenditures [1][2]. Group 1: Offering Details - The public offering was priced at $0.915 per share, with each share sold together with two warrants, each exercisable at $1.098 per share [1]. - The offering closed on September 4, 2025, and the warrants will expire on the fifth anniversary of their issuance [1][2]. - The offering was conducted under a registration statement declared effective by the SEC on August 27, 2025 [4]. Group 2: Company Overview - Nova LifeStyle, Inc. is an innovative designer and distributor of modern lifestyle furniture, including sofas, dining room furniture, and office furniture, targeting middle and upper middle-income consumers [6]. - The company's product lines include the Nova Brands and Diamond Sofa, featuring urban contemporary styles that integrate comfort and functionality [6].

Core Viewpoint - Artelo Biosciences, Inc. has announced a public offering of common stock and pre-funded warrants, aiming to raise approximately $3.0 million to support its clinical-stage pharmaceutical initiatives focused on treating various medical conditions [1][6]. Group 1: Offering Details - The company is offering 640,924 shares of common stock at a price of $4.40 per share and pre-funded warrants to purchase up to 40,894 shares at a price of $4.399 per warrant [1]. - The total gross proceeds from the offering are expected to be around $3.0 million before deducting underwriting discounts and other expenses [1]. - Underwriters have a 45-day option to purchase an additional 102,272 shares to cover over-allotments [1]. Group 2: Underwriting and Registration - R.F. Lafferty & Co., Inc. is acting as the sole book-running manager for the offering [2]. - The shares and warrants are being offered under a "shelf" registration statement filed with the SEC, which was declared effective on July 14, 2023 [2]. Group 3: Company Overview - Artelo Biosciences is a clinical-stage pharmaceutical company focused on developing treatments that modulate lipid-signaling pathways for conditions such as cancer, pain, and dermatologic issues [6]. - The company is also implementing a digital asset treasury strategy to enhance its financial position [6].